Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 3

3(33.3%)

Phase 2

1(11.1%)

9Total

Phase 1(5)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04984577Phase 2Suspended

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Role: lead

NCT03650933Phase 3Recruiting

A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

Role: lead

NCT04205565Phase 3Recruiting

Study on Clinical Effectiveness of L-Oxiracetam Injection

Role: lead

NCT05588531Phase 1Completed

Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers

Role: lead

NCT03003039Phase 1Completed

A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

Role: lead

NCT04218513Phase 1Completed

Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

Role: lead

NCT04219865Phase 1Completed

Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection

Role: lead

NCT04670809Phase 3Unknown

Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

Role: lead

NCT02717741Phase 1Unknown

A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor

Role: lead

All 9 trials loaded